On December 3, 2025, Simcere Pharmaceutical Group (2096.HK) and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. (2630.HK) entered into a licensing agreement for deuterium remidevir hydrobromide. Under the agreement, Simcere Pharmaceutical will obtain exclusive licensing rights in Greater China for deuterium remidevir hydrobromide dry suspension for the indications of treating respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection. This collaboration will further strengthen Simcere Pharmaceutical's product portfolio in the anti-infective field.

Deuterremidevir hydrobromide is an oral nucleoside analogue with broad-spectrum anti-RNA virus potential, exerting its effect by inhibiting viral RNA-dependent RNA polymerase (RdRp). A Phase II clinical trial in China for the treatment of RSV infection in infants (1-24 months) has been completed. Clinical results showed that deuterremidevir hydrobromide dry suspension has good anti-RSV efficacy and safety. Based on the positive results of this clinical trial, deuterremidevir hydrobromide dry suspension received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Previously, deuterremidevir hydrobromide tablets had been routinely approved in my country for the treatment of mild to moderate COVID-19 infection in adults.

Dr. Tian Guanghui, Chairman and General Manager of Wangshan Wangshui, stated, "Deuterated remdesivir hydrobromide dry suspension has received Breakthrough Therapy designation and is expected to become the world's first approved nucleoside analog anti-RSV drug. This exclusive licensing collaboration with Simcere Pharmaceutical will accelerate the development of deuterated remdesivir hydrobromide for respiratory syncytial virus infection and human metapneumovirus infection indications, providing patients with better treatment options as soon as possible."

Zhou Gaobo, Chief Investment Officer of Simcere Pharmaceutical, said: "RSV virus can cause respiratory infections in people of all ages, especially infants, the elderly, and people with weakened immune systems. Currently, there is still a lack of effective drug treatments. We are pleased to cooperate with Wangshan Wangshui to jointly promote the development and commercialization of new antiviral drugs, so that patients can use more effective drugs as soon as possible."